



INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP  
ANNUAL MEETING - BARCELONA 2004  
PROGRAM

Thursday March 4

- 13.00 – 14.00 Registration at the Hotel Alexandra, Barcelona
- 14.00 – 14.30 OPENING REMARKS *E. Zucca, Bellinzona CH*
- OVERVIEW OF THE STATUS OF THE ONGOING STUDIES**
- 14.30 – 15.45 IELSG 4: Chemotherapy vs chemotherapy plus irradiation in diffuse large-cell gastric lymphoma *G. Martinelli, Milano I*  
IELSG 10: A phase II study of CHOP, with intrathecal methotrexate followed by radiotherapy, in patients with primary testicular non-Hodgkin's lymphoma *U. Vitolo, Torino I*  
IELSG 11: Retrospective evaluation of localized primary cutaneous B-cell lymphomas *S. Cortelazzo, Bergamo I*  
IELSG 17: Multi-institutional retrospective analysis of intravascular lymphomatosis *A. Ferreri, M. Ponzoni, Milan I*  
IELSG 18: Retrospective international survey on primary effusion lymphomas *A. Conconi, Novara I*
- 15.45 – 16.15 COFFEE BREAK
- 16.15 – 16.30 MOLECULAR BIOLOGY STUDIES *F. Bertoni, Bellinzona CH*  
IELSG 12: Chromosome 11q amplification in primary extranodal diffuse large B-cell lymphomas  
IELSG 16: RT-PCR detection of the t(11;18) translocation as a predictor of outcome in extranodal marginal lymphoma of MALT type
- 16.30 – 17.30 IELSG 14: Retrospective evaluation of primary bone lymphoma *D. Christie, Tugun AUS*  
IELSG 15: Retrospective evaluation of primary breast lymphoma *G. Ryan, Melbourne AUS*
- 17.30 – 18.00 IELSG 19: Multicenter randomized trial of chlorambucil versus chlorambucil plus rituximab in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) *E. Zucca, Bellinzona CH*
- 18.00 – 18.15 BREAK
- EDUCATIONAL LECTURE**
- 18.15 – 19.30 **What have we learned from CLL and how can it be used in the management of NHLs ?** *E. Montserrat, Barcelona E*
- 20.30 DINNER

ANNUAL MEETING - BARCELONA 2004

PROGRAM

Friday March 5

- 8.30 – 9.30 DISCUSSION OF ADMINISTRATIVE ISSUES  
Approval of «By-laws» and election of «Scientific board»
- 9.30 – 10.30 PCNSL  
Report from the International PCNSL Collaborative Group *F. Cavalli, Bellinzona CH*  
IELSG 20: Randomized phase II trial on primary chemotherapy with high-dose methotrexate, alone or associated with high-dose cytarabine, followed by response- and age-tailored radiotherapy for immunocompetent patients with newly diagnosed primary central nervous system lymphoma *A. Ferreri, Milan I*  
IELSG 21: Salvage therapy with idarubicin in immunocompetent patients with relapsed or refractory primary central nervous system lymphomas *A. Ferreri, Milan I*
- 10.30 – 10.45 COFFEE BREAK
- 10.45 – 11.45 ADDITIONAL (MORE OR LESS NEW) PROPOSALS  
IELSG 22: Gastric irradiation for MALT lymphoma: a retrospective study  
*M. Gospodarowicz, Toronto CA*  
IELSG 23: Retrospective evaluation of primary head and neck lymphoma  
*S. Cortelazzo, Bergamo, I*  
Prospective clinico-pathological phase II study in marginal zone lymphoma of the ocular adnexae *J. Radford, Manchester UK*  
Trial of cytotoxic T cell therapy for post transplant lymphoproliferative disease  
*D. Crawford, Edimburgh UK*  
Tissue microarrays and gene expression from paraffin-embedded tissues: new possibilities for the IELSG studies *M. Ponzoni, Milan, F. Bertoni, Bellinzona CH*
- 11.45 – 12.00 CLOSING REMARKS *F. Cavalli, Bellinzona, CH*